Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL10827355 | 0.98 | MAPT (0.56) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL7979826 | 0.83 | LMNA (0.53) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL2288364 | 0.81 | MAPT (0.64) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL4851241 | 0.81 | SMN1; SMN2 (0.66) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL12336328 | 0.80 | MAPT (0.54) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL23720127 | 0.79 | L3MBTL1 (0.58) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL12336440 | 0.78 | MAPT (0.55) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL3826992 | 0.78 | MAPT (0.60) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL1999954 | 0.78 | ALDH1A1 (0.61) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL13385658 | 0.77 | L3MBTL1 (0.56) | MAPTMEN1KMT2AHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2550266-B1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | AMITECH THERAPEUTICS SOLUTIONS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-20160237064-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ALLOSTERIC KINASE INHIBITION | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160096824-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2016-04-07 | — | — | US | disclosed |
| US-9260417-B2 | Therapeutic methods and compositions involving allosteric kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9212151-B2 | Heterocyclic compounds useful for kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212151-B2 | Heterocyclic compounds useful for kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150158828-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2015-06-11 | — | — | US | disclosed |
| US-20150158828-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2015-06-11 | — | — | US | disclosed |
| US-8957216-B2 | Heterocyclic compounds useful for kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957216-B2 | Heterocyclic compounds useful for kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20140296268-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ALLOSTERIC KINASE INHIBITION | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2014-10-02 | — | — | US | disclosed |
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | AMITECH THERAPEUTIC SOLUTIONS INC (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | AMITECH THERAPEUTIC SOLUTIONS INC (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2011119894-A2 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | KINAGEN, INC (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | MAP4K2, MAP3K20, MAP3K19 | MAPT 4114/4885MEN1 2954/4885KMT2A 900/4885 |
| US-20160237064-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ALLOSTERIC KINASE INHIBITION | TIE1, PRKCH, PACSIN2 | MAPT 3053/4885MEN1 3632/4885KMT2A 1922/4885 |
| US-20150158828-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | MAP4K2, MAP3K20, MAP3K19 | MAPT 4114/4885MEN1 2954/4885KMT2A 900/4885 |
| US-20140296268-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ALLOSTERIC KINASE INHIBITION | TIE1, PRKCH, PACSIN2 | MAPT 3053/4885MEN1 3632/4885KMT2A 1922/4885 |
| US-20160096824-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | MAP4K2, MAP3K20, MAP3K19 | MAPT 4114/4885MEN1 2954/4885KMT2A 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.